Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity

Yong Mao, Chiang Yu, Tao Shih Hsieh, John L. Nitiss, Angela A. Liu, Huimin Wang, Leroy-Fong Liu

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Two mutations, R450Q and P803S, in the coding region of the human topoisomerase IIα gene have been identified in the atypical multidrug resistant (at-MDR) cell line, CEM/VM-1, which exhibits resistance to many structurally diverse topoisomerase II-targeting antitumor drugs such as VM- 26, doxombicin, m-AMSA, and mitoxantrone. The R450Q mutation mapped in the ATP utilization domain, while the P803S mutation mapped in the vicinity of the active site tyrosine of human topoisomerase IIα. However, the roles of these two mutations in conferring multidrug resistance are unclear. To study the roles of these two mutations in conferring multidrug resistance, we have characterized the recombinant human DNA topoisomerase IIα containing either single or double mutations. We show that both R450Q and P803S mutations confer resistance in the absence of ATP. However, in the presence of ATP, the R450Q, but not the P803S, mutation can confer multidrug resistance. The R450Q enzyme was shown to exhibit impaired ATP utilization both for enzyme catalysis and for its ability to form the circular protein clamp. Interestingly, an unrelated mutation, G437E, which is also located in the same domain as the R450Q mutation, exhibited multidrug hypersensitivity in the absence of ATP. However, in the presence of ATP, the G437E enzyme is only minimally hypersensitive to various topoisomerase II drugs. In contrast to the R450Q enzyme, the G437E enzyme exhibited enhanced ATP utilization for enzyme catalysis. In the aggregate, these results support the notion that the multidrug resistance and sensitivity of these mutant enzymes are due to a specific defect in ATP utilization during enzyme catalysis.

Original languageEnglish
Pages (from-to)10793-10800
Number of pages8
JournalBiochemistry
Volume38
Issue number33
DOIs
Publication statusPublished - Aug 17 1999
Externally publishedYes

Fingerprint

Type II DNA Topoisomerase
Multiple Drug Resistance
Adenosine Triphosphate
Mutation
Enzymes
Catalysis
Amsacrine
Teniposide
Mitoxantrone
Clamping devices
Catalyst supports
Antineoplastic Agents
Recombinant DNA
Tyrosine
Genes
Cells
Catalytic Domain
Hypersensitivity
Defects
Cell Line

ASJC Scopus subject areas

  • Biochemistry

Cite this

Mao, Y., Yu, C., Hsieh, T. S., Nitiss, J. L., Liu, A. A., Wang, H., & Liu, L-F. (1999). Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity. Biochemistry, 38(33), 10793-10800. https://doi.org/10.1021/bi9909804

Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity. / Mao, Yong; Yu, Chiang; Hsieh, Tao Shih; Nitiss, John L.; Liu, Angela A.; Wang, Huimin; Liu, Leroy-Fong.

In: Biochemistry, Vol. 38, No. 33, 17.08.1999, p. 10793-10800.

Research output: Contribution to journalArticle

Mao, Y, Yu, C, Hsieh, TS, Nitiss, JL, Liu, AA, Wang, H & Liu, L-F 1999, 'Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity', Biochemistry, vol. 38, no. 33, pp. 10793-10800. https://doi.org/10.1021/bi9909804
Mao Y, Yu C, Hsieh TS, Nitiss JL, Liu AA, Wang H et al. Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity. Biochemistry. 1999 Aug 17;38(33):10793-10800. https://doi.org/10.1021/bi9909804
Mao, Yong ; Yu, Chiang ; Hsieh, Tao Shih ; Nitiss, John L. ; Liu, Angela A. ; Wang, Huimin ; Liu, Leroy-Fong. / Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity. In: Biochemistry. 1999 ; Vol. 38, No. 33. pp. 10793-10800.
@article{2024fd5df9d5456396d8f2a72f918a6e,
title = "Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity",
abstract = "Two mutations, R450Q and P803S, in the coding region of the human topoisomerase IIα gene have been identified in the atypical multidrug resistant (at-MDR) cell line, CEM/VM-1, which exhibits resistance to many structurally diverse topoisomerase II-targeting antitumor drugs such as VM- 26, doxombicin, m-AMSA, and mitoxantrone. The R450Q mutation mapped in the ATP utilization domain, while the P803S mutation mapped in the vicinity of the active site tyrosine of human topoisomerase IIα. However, the roles of these two mutations in conferring multidrug resistance are unclear. To study the roles of these two mutations in conferring multidrug resistance, we have characterized the recombinant human DNA topoisomerase IIα containing either single or double mutations. We show that both R450Q and P803S mutations confer resistance in the absence of ATP. However, in the presence of ATP, the R450Q, but not the P803S, mutation can confer multidrug resistance. The R450Q enzyme was shown to exhibit impaired ATP utilization both for enzyme catalysis and for its ability to form the circular protein clamp. Interestingly, an unrelated mutation, G437E, which is also located in the same domain as the R450Q mutation, exhibited multidrug hypersensitivity in the absence of ATP. However, in the presence of ATP, the G437E enzyme is only minimally hypersensitive to various topoisomerase II drugs. In contrast to the R450Q enzyme, the G437E enzyme exhibited enhanced ATP utilization for enzyme catalysis. In the aggregate, these results support the notion that the multidrug resistance and sensitivity of these mutant enzymes are due to a specific defect in ATP utilization during enzyme catalysis.",
author = "Yong Mao and Chiang Yu and Hsieh, {Tao Shih} and Nitiss, {John L.} and Liu, {Angela A.} and Huimin Wang and Leroy-Fong Liu",
year = "1999",
month = "8",
day = "17",
doi = "10.1021/bi9909804",
language = "English",
volume = "38",
pages = "10793--10800",
journal = "Biochemistry",
issn = "0006-2960",
publisher = "American Chemical Society",
number = "33",

}

TY - JOUR

T1 - Mutations of human topoisomerase IIα affecting multidrug resistance and sensitivity

AU - Mao, Yong

AU - Yu, Chiang

AU - Hsieh, Tao Shih

AU - Nitiss, John L.

AU - Liu, Angela A.

AU - Wang, Huimin

AU - Liu, Leroy-Fong

PY - 1999/8/17

Y1 - 1999/8/17

N2 - Two mutations, R450Q and P803S, in the coding region of the human topoisomerase IIα gene have been identified in the atypical multidrug resistant (at-MDR) cell line, CEM/VM-1, which exhibits resistance to many structurally diverse topoisomerase II-targeting antitumor drugs such as VM- 26, doxombicin, m-AMSA, and mitoxantrone. The R450Q mutation mapped in the ATP utilization domain, while the P803S mutation mapped in the vicinity of the active site tyrosine of human topoisomerase IIα. However, the roles of these two mutations in conferring multidrug resistance are unclear. To study the roles of these two mutations in conferring multidrug resistance, we have characterized the recombinant human DNA topoisomerase IIα containing either single or double mutations. We show that both R450Q and P803S mutations confer resistance in the absence of ATP. However, in the presence of ATP, the R450Q, but not the P803S, mutation can confer multidrug resistance. The R450Q enzyme was shown to exhibit impaired ATP utilization both for enzyme catalysis and for its ability to form the circular protein clamp. Interestingly, an unrelated mutation, G437E, which is also located in the same domain as the R450Q mutation, exhibited multidrug hypersensitivity in the absence of ATP. However, in the presence of ATP, the G437E enzyme is only minimally hypersensitive to various topoisomerase II drugs. In contrast to the R450Q enzyme, the G437E enzyme exhibited enhanced ATP utilization for enzyme catalysis. In the aggregate, these results support the notion that the multidrug resistance and sensitivity of these mutant enzymes are due to a specific defect in ATP utilization during enzyme catalysis.

AB - Two mutations, R450Q and P803S, in the coding region of the human topoisomerase IIα gene have been identified in the atypical multidrug resistant (at-MDR) cell line, CEM/VM-1, which exhibits resistance to many structurally diverse topoisomerase II-targeting antitumor drugs such as VM- 26, doxombicin, m-AMSA, and mitoxantrone. The R450Q mutation mapped in the ATP utilization domain, while the P803S mutation mapped in the vicinity of the active site tyrosine of human topoisomerase IIα. However, the roles of these two mutations in conferring multidrug resistance are unclear. To study the roles of these two mutations in conferring multidrug resistance, we have characterized the recombinant human DNA topoisomerase IIα containing either single or double mutations. We show that both R450Q and P803S mutations confer resistance in the absence of ATP. However, in the presence of ATP, the R450Q, but not the P803S, mutation can confer multidrug resistance. The R450Q enzyme was shown to exhibit impaired ATP utilization both for enzyme catalysis and for its ability to form the circular protein clamp. Interestingly, an unrelated mutation, G437E, which is also located in the same domain as the R450Q mutation, exhibited multidrug hypersensitivity in the absence of ATP. However, in the presence of ATP, the G437E enzyme is only minimally hypersensitive to various topoisomerase II drugs. In contrast to the R450Q enzyme, the G437E enzyme exhibited enhanced ATP utilization for enzyme catalysis. In the aggregate, these results support the notion that the multidrug resistance and sensitivity of these mutant enzymes are due to a specific defect in ATP utilization during enzyme catalysis.

UR - http://www.scopus.com/inward/record.url?scp=0033578339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033578339&partnerID=8YFLogxK

U2 - 10.1021/bi9909804

DO - 10.1021/bi9909804

M3 - Article

C2 - 10451375

AN - SCOPUS:0033578339

VL - 38

SP - 10793

EP - 10800

JO - Biochemistry

JF - Biochemistry

SN - 0006-2960

IS - 33

ER -